Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
5 studies found for:    14996676 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated EXtended Therapy in Hepatitis C Genotype 3 Infected Patients
Condition: Chronic Hepatitis C
Intervention: Drug: Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)
2 Completed Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Condition: Chronic Hepatitis C
Interventions: Drug: Peg-IFN + WB RBV for 16 weeks;   Drug: Peg-IFN + LD RBV for 16 weeks;   Drug: Peg-IFN + WB RBV for 24 weeks;   Drug: Peg-IFN + WB RBV for 48 weeks;   Drug: Peg-IFN + LD RBV for 24 weeks
3 Unknown  Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan
Condition: Chronic Hepatitis C
Intervention: Drug: Pegylated interferon alfa and ribavirin
4 Completed A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients
Conditions: Chronic Hepatitis C;   Genotype
Interventions: Drug: pegylated interferon alpha 2a and ribavirin;   Drug: Pegylated interferon alfa-2a and ribavirin
5 Completed
Has Results
Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients
Condition: Hepatitis C, Chronic
Intervention: Drug: Pegylated interferon alfa-2a plus ribavirin

Indicates status has not been verified in more than two years